BUHLMANN News

IBDoc® Talk #2 – Tips and Tricks Teleconference

Health Canada Licence: 98903, Device class: 3  BÜHLMANN IBDoc® is not available for sale in the US. IBDoc® is the first self-testing application ...
Read More

Visit the BUHLMANN Booth at DDW 2019

Visit booth #842 to get an update on our Calprotectin and Therapeutic Drug Monitoring product portfolio:

Interview: BUHLMANN fCAL ELISA in a Clinical Laboratory- Expert User Perspectives

BÜHLMANN fCAL® ELISA is FDA 510(k) cleared.  For in vitro Diagnostic Use. Health Canada License: 80726 In this Video You will Learn:

Connect with BUHLMANN at CDDW 2019!

Canadian Digestive Diseases Week (CDDW) 2019 BUHLMANN Diagnostics Corp Booth: #116 Mar 1 - 3, 2019 | Fairmont Banff Springs ...
Read More

BUHLMANN Diagnostics Corp Announces New Distribution Agreement with Meridian Biosciences, Inc.

BUHLMANN Diagnostic Corp (BDC), Amherst, NH is proud to announce they have entered into a distribution agreement with Meridian Bioscience, ...
Read More

Two New fCAL turbo Video Testimonials from Portugal

BÜHLMANN fCAL® turbo is for Research Use Only in the US. Not to be used in diagnostic procedures. Health Canada ...
Read More

Clinical Trial Combines New Symptom App with IBDoc

Read a recent article from University of Otago on the success of a new smartphone app, IBDSmart, in synergy with ...
Read More
Loading...